Used primarily in pharmaceutical research as a key intermediate in the synthesis of selective kinase inhibitors. It shows particular relevance in the development of compounds targeting receptor tyrosine kinases involved in cancer cell proliferation and angiogenesis. Its structure supports high binding affinity to specific enzyme active sites, making it valuable in optimizing drug candidates for oncology. Additionally, it has been explored in the design of central nervous system agents due to its ability to cross the blood-brain barrier, offering potential in treating neurodegenerative diseases and psychiatric disorders. The compound's fluorobenzyl and benzimidazole moieties contribute to metabolic stability and enhanced bioavailability in preclinical studies.